lenvatinibi

Lenvatinib, sometimes written as lenvatinibi in some languages, is an oral small-molecule anticancer medication. It is a multi-target tyrosine kinase inhibitor that blocks several receptors involved in tumor angiogenesis and growth, including vascular endothelial growth factor receptors 1–3 (VEGFR-1 to VEGFR-3), fibroblast growth factor receptors 1–4 (FGFR-1 to FGFR-4), RET, and KIT. By inhibiting these pathways, lenvatinib can reduce tumor blood vessel formation and tumor cell proliferation.

Approved indications include differentiated thyroid carcinoma that is not responsive to radioactive iodine, unresectable or metastatic hepatocellular carcinoma, and, in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus, advanced renal cell carcinoma after failure of prior anti-angiogenic therapy. Lenvatinib is also studied in a range of other cancers in clinical trials. Dosing and administration depend on the indication and patient characteristics, and it is taken orally, usually once daily, with or without food.

Common adverse effects reported with lenvatinib include hypertension, fatigue, decreased appetite and weight loss, diarrhea, nausea, stomatitis, and proteinuria. Serious risks can include liver toxicity, thromboembolic events, wound-healing impairment, and cardiovascular complications. Patients are monitored for blood pressure, kidney function, liver enzymes, and signs of bleeding or proteinuria, and therapy may be adjusted or temporarily halted based on tolerability and safety concerns.

Lenvatinib is marketed under the brand name Lenvima by Eisai. It is a prescription medication used in oncology with a variety of dosing regimens tailored to the cancer type and patient factors.